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For initiation of an immune response, resting T cellsmust reprogram their metabolism. Continuing the
‘‘From the Field’’ series (see Editorial [2007] 26, 131), Jones and Thompson draw attention to the im-
portance of metabolism during T cell activation and consider how this process is regulated by recep-
tor-mediated signal transduction.Introduction
Stimulation through the T cell receptor
(TCR) and costimulatory receptors trig-
gers a switch in T cell differentiation
from a quiescent (resting) state to an
activated state characterized by rapid
rates of growth and proliferation and
the acquisition of effector function.
The decision to proliferate—to in-
crease biomass and replicate the ge-
nome in order to create two daughter
cells—presents a substantial bioener-
getic challenge. A T cell must substan-
tially increase ATP production and
acquire or synthesize the substrates
(lipids, proteins, and nucleic acids)
needed to support growth at a suffi-
cient rate to meet the demands of pro-
liferation. Without sufficient support for
their increased bioenergetic needs,
activated T cells die by apoptosis.
Recent evidence indicates that this
increase in cellular metabolism is not
a homeostatic response to the in-
creased consumption of ATP and mac-
romolecules upon activation. Rather,
specific signal transduction pathways
direct nutrient uptake and metabolism
during T cell activation. How the intra-
cellular metabolism of acquired nutri-
ents is redirected from mitochondrial
oxidative phosphorylation (OXPHOS)
to synthetic metabolic pathways dur-
ing T cell growth and proliferation is
poorly understood.
T Cell Activation Triggers
a Metabolic Conversion
Quiescent (naive and memory) and ac-
tivated T cells display different meta-
bolic signatures (Table 1). Resting T
cells have fewer energetic and biosyn-thetic demands relative to the acti-
vated state and devote the majority
of energy metabolism toward house-
keeping functions. They display
a lower rate of nutrient uptake and de-
rive most of their ATP from catabolic
processes that fuel OXPHOS (Krauss
et al., 2001). In the absence of extrinsic
signals for maintaining homeostatic
processes, quiescent T cells undergo
progressive atrophy (Rathmell et al.,
2000). (For a more extensive review
of the metabolism of quiescent lym-
phocytes, please see Fox et al.
[2005]). Upon stimulation, T cells un-
dergo conversion from a resting state
to one of active growth. Anabolic pro-
cesses such as protein and lipid syn-
thesis are increased, whereas cata-
bolic processes including b-oxidation
are actively suppressed. One hallmark
of this metabolic conversion is that,
despite adequate oxygen to support
complete oxidation of glucose, cellular
ATP production switches from OX-
PHOS to high throughput glycolysis.
As will be discussed later, this
switch to glycolytic energy production,
known as aerobic glycolysis, is impor-
tant for both energy production and
biosynthetic programs during T cell
activation.
Effective T cell activation requires
two signals: an antigen-specific signal
delivered by the TCR and a costimula-
tory signal, delivered by surface recep-
tors such as CD28. Antigen-specific
signals via the TCR drive a program
of transcription and translation. This
program provides the instructional
code for proliferation. Initiation of this
program commits the T cell to an ener-Immunitygetically demanding process that can
only proceed if there are sufficient in-
tracellular resources. Signal transduc-
tion pathways downstream of costi-
mulatory receptors such as CD28
actively upregulate pathways of nutri-
ent uptake, glycolytic ATP production,
and macromolecular synthesis to facil-
itate the metabolic conversion of T
cells from quiescence to proliferation
(Figure 1). From a metabolic perspec-
tive, costimulation can be viewed as
a fuel signal—ensuring that nutrient
uptake and energy production meets
or exceeds the bioenergetic demand
of proliferation.
Glycolysis: A Source of Energy
and Metabolic Intermediates
during Cell Growth
Glucose is a critical metabolite for pro-
liferating cells. It serves as the primary
substrate for ATP generation, is an in-
termediate in glycosylation reactions,
and is an essential carbon source for
the synthesis of other macromole-
cules. T cell activation triggers a rapid
increase in glucose uptake and glyco-
lytic metabolism (Roos and Loos,
1973). T cell activation also triggers
the rapid transcription of genes encod-
ing glycolytic enzymes including
glyceraldehyde-3-phosphate dehy-
drogenase, triose-phosphate isomer-
ase, aldolase, and enolase. Maximal
glycolytic metabolism requires both
a TCR signal and costimulation via
CD28 (Frauwirth et al., 2002). TCR ac-
tivation along with CD28 costimulation
triggers the activity of phosphatidyli-
nositol 30-kinase (PI3K), which,
through conversion of the membrane27, August 2007 ª2007 Elsevier Inc. 173
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Quiescent T Cells Activated T Cells
Metabolic Signature Catabolic Anabolic
Primary Source of ATP Generation OXPHOS Glycolysis
Nutrient Uptake Low High rate of glucose and amino acid
uptake
Glycolytic Rate Low High
Biosynthesis Homeostatic Increased lipid, protein, and nucleic
acid synthesis
Catabolic Processes Interchangeable degradation of
glucose, amino acids, and lipids for
ATP generation
Suppression of b-oxidation; Net
amino acid synthesis
Growth Profile Progressive atrophy without basal
extracellular signaling
Exponential growth and proliferation
Quiescent (resting) and activated T cells display distinct metabolic signatures on the basis of their bioenergetic and biosynthetic
requirements. Naive T cells derive the majority of their ATP through catabolic metabolism of intracellular contents (glucose, amino
acids, and lipids) and oxidative phosphorylation (OXPHOS) and maintain basal rates of nutrient uptake, glycolysis, and biosynthe-
sis. Activated T cells switch to an anabolic metabolic profile characterized by increased rates of nutrient uptake, glycolysis, and
biosynthesis and suppression of catabolic pathways such as b-oxidation.lipid PIP2 to PIP3, leads to the activa-
tion of the serine-threonine kinase
Akt. The lipid phosphatase PTEN an-
tagonizes Akt activation by dephos-
phorylating PIP3. Akt promotes in-
creased cellular glucose metabolism
by stimulating the localization of the
glucose transporter Glut1 to the
plasma membrane, thus facilitating in-
creased glucose uptake (Frauwirth
et al., 2002; Rathmell et al., 2003). In
addition, Akt increases glycolytic me-
tabolism by stimulating the activity of
hexokinase and phosphofructokinase,
both rate-limiting enzymes of the gly-
colytic pathway. The effects of Akt on
glucose metabolism in lymphocytes
are antagonized by the inhibitory re-
ceptor CTLA-4, suggesting that antag-
onists of T cell activation may function
in part by disrupting glucose metabo-
lism. Other costimulatory molecules
including OX40 and 4-1BB can also
activate the PI3K-Akt pathway and
contribute to the regulation of nutrient
uptake and metabolism in activated T
cells. In addition, Notch signaling has
been reported to stimulate glycolytic
metabolism in thymocytes through ac-
tivation of PI3K-Akt (Ciofani and Zu-
niga-Pflucker, 2005). CD19 in B cells
and DAP10 in NK cells appear to initi-
ate a similar metabolic signaling path-
way to that initiated in T cells by CD28.
Signaling downstream of cytokine re-174 Immunity 27, August 2007 ª2007 Elsceptors can augment aerobic glycolysis
in proliferating lymphocytes by stimu-
lating the PI3K-Akt pathway or by en-
hancing Jak-Stat-dependent regulation
of glycolytic genes (Fox et al., 2005).
Each molecule of glucose pro-
cessed by glycolysis yields two mole-
cules each of ATP, NADH, and pyru-
vate. In proliferating lymphocytes, the
majority of the pyruvate produced is
converted to lactate, which allows the
recycling of NADH back to NAD+ to
maintain glycolytic flux. Although the
energetic yield of aerobic glycolysis is
much smaller than OXPHOS, under
conditions of unlimited glucose sup-
ply, glycolysis produces ATP substan-
tially faster. Therefore, stimulating glu-
cose uptake and glycolysis is the most
direct way a cell can increase its en-
ergy production to meet the demands
of anabolic growth.
In addition to providing energy for
proliferating T cells, glycolysis also
generates metabolic intermediates
critical for cell growth. Metabolism of
glucose through the pentose phos-
phate shunt generates both ribose-5-
phosphate, a key intermediate in nu-
cleotide biosynthesis, and NADPH,
which supplies reductive power for
both nucleotide and fatty acid biosyn-
thesis. Glycolytic intermediates also
contribute to protein and lipid synthe-
sis. 3-phosphoglycerate provides theevier Inc.carbon backbone for the production
of the amino acids serine and glycine.
Glycerol moieties for phospholipid
synthesis are derived from dihydroxy-
acetone phosphate. Finally, the glyco-
lytic end product pyruvate can be im-
ported into the mitochondria where it
can be converted into substrates for
the production of additional amino
acids or for fatty acid synthesis. Pyru-
vate metabolism in the mitochondria
also maintains mitochondrial mem-
brane potential, thus suppressing apo-
ptosis in proliferating lymphocytes.
Protein Translation in
Lymphocytes
T cell activation is accompanied by in-
creased rates of protein synthesis that
is essential for supporting cell growth
and effector function. A key regulator
of protein synthesis in T cells is
the mammalian Target of Rapamycin
(mTOR) (Wullschleger et al., 2006).
mTOR modulates the rate of protein
synthesis by regulating both the avail-
ability of amino acids and the process
of cap-dependent translation. Phos-
phorylation by mTOR promotes the ini-
tiation of cap-dependent translation
by altering the activity of components
of the translational machinery includ-
ing the translational inhibitor 4E-
BP1, the translation initiation factor
EIF2B, and ribosomal p70 S6 kinase.
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CommentaryFigure 1. Metabolic Pathways of Growth and Proliferation in T Cells
Stimulation of the TCR and CD28 induces PI3K-dependent activation of Akt in T lymphocytes, leading to multiple changes in cellular metabolism. Akt
facilitates increased glucose metabolism by promoting surface expression of the glucose transporter Glut1 and enhancing the activity of glycolytic
enzymes. The multiple fates of glucose (Glc) include glycolytic processing to produce ATP and pyruvate, production of ribose 5-phosphate (Rib-5-P)
and NADPH for nucleotide biosynthesis by the pentose phosphate shunt (PPS), or entry into the tricarboxylic acid (TCA) cycle for biosynthesis or ATP
generation by the electron transport chain (ETC). Mitochondrial-dependent reactive oxygen species (ROS) are stimulated by TCR-derived Ca2+ sig-
nals. Glucose-derived citrate (Cit) is exported to the cytosol and processed by ATP citrate lyase (ACL) to acetyl-CoA (Ac-CoA) and malate, which is
shuttled back into the mitochondria. Cytosolic acetyl-CoA is used for the synthesis of phospholipids, cholesterol, and isoprenoids. Glutamine (Gln) is
deaminated in the mitochondria for generating a-ketoglutarate (aKG), which is metabolized further so that the oxaloacetate (OAA) required for con-
tinued biosynthesis could be regenerated. mTOR and PIM2 are independent regulators of protein translation. TCR- and CD28-dependent activation
of mTOR promotes increased surface expression of amino acid (AA) transporters. Akt promotes TCR- and CD28-dependent mTOR activity by re-
lieving inhibition of RhebGTP by the TSC1-TSC2 complex. The LKB1-AMPK pathway antagonizes mTOR activity by activating the TSC1-TSC2 com-
plex in response to bioenergetic stress. Jak-Stat-dependent signal transduction downstream of cytokine receptors promotes increased growth
through transcriptional regulation of PIM2 and glycolytic genes.Rapamycin, which is a potent inhibitor
of mTOR, suppresses cap-dependent
protein translation. Rapamycin is an
immunosuppressant and functions to
suppress lymphocyte proliferation in
part by inducing a G1 cell-cycle arrest
(Kay et al., 1991).
As with glucose metabolism, protein
metabolism in proliferating T cells is
regulated by TCR and CD28 signals
through the activation of the PI3K-Akt
pathway. Akt regulates mTOR function
by phosphorylating TSC2. This phos-
phorylation disrupts the ability of the
TSC1-TSC2 complex to inhibit Rheb,
a GTP-binding protein that serves as
an mTOR activator (Inoki et al., 2002).
T cells with enhanced Akt activity dis-
play increased cell size because of
an enhancement of mTOR-dependentgrowth (Rathmell et al., 2003). The on-
cogenic kinases of the PIM family also
function to couple cytokine-mediated
signals to translational control. PIM2
enhances protein translation through
concomitant inhibition of 4E-BP1 and
activation of the initiation factor eIF4E
(Hammerman et al., 2005). In mice,
combined deficiency of the Akt1,
Pim1, and Pim2 genes leads to de-
creased resting T cell size, and the in-
hibition of both the PI3K-Akt-mTOR
and PIM pathways leads to dramatic
defects in T cell growth and prolifera-
tion. Thus, the PI3K-Akt-mTOR and
PIM pathways function as redundant
but essential mediators of TCR- and
CD28-dependent translation control.
Amino acid availability represents an
additional regulatory step for proteinImmunitytranslation. mTOR signaling also pro-
motes increased amino acid uptake
by regulating the surface expression
of amino acid transporters. The activa-
tion surface marker 4F2hc is a rapamy-
cin-sensitive component of several
amino acid transporters and is upregu-
lated by CD28 costimulation (Gottes-
diener et al., 1988). Furthermore, the
maintenance of nutrient transporters
on the cell surface depends on ongo-
ing signal transduction. When receptor
signaling is interrupted, the turnover
of nutrient transporters rapidly de-
creases the rate of nutrient uptake
and terminates growth (Edinger et al.,
2003).
Antigen-presenting cells (APCs)
can also affect T cell activation by
controlling extracellular amino acid27, August 2007 ª2007 Elsevier Inc. 175
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dritic cells (DCs) can limit the extracel-
lular availability of the essential amino
acid tryptophan through degradation
by the enzyme indoleamine 2,3-dioxy-
genase (IDO) . Tryptophan catabolism
can limit T cell responsiveness by in-
ducing anergy (Munn et al., 2005).
CTLA-4, a regulator of T cell anergy
that both negatively regulates CD28-
dependent glucose metabolism and
stimulates IDO activity in DCs, pro-
motes T cell tolerance in part through
its effects on tryptophan catabolism
(Grohmann et al., 2002). The regulation
of cellular metabolism in APCs may
represent an additional control point
for T cell activation.
The Mitochondria as
a Biosynthetic Hub
The primary site for energy generation
in vegetative cells is the mitochon-
drion. Enzymes of the tricarboxylic
acid (TCA)-cycle resident in the mito-
chondrial matrix facilitate the com-
plete oxidation of pyruvate for ATP
production through electron-trans-
port-coupled OXPHOS. Pyruvate gen-
erated from glycolysis is converted to
acetyl-CoA in the mitochondrion. The
resulting acetyl-CoA then enters the
TCA cycle by condensing with oxalo-
acetic acid (OAA) to form citrate. Cit-
rate can be sequentially processed
back to OAA by enzymes of the TCA
cycle, generating reducing equivalents
(NADH and FADH2) and CO2 in the
process. The electrons from NADH
and FADH2 can be donated to com-
plex I and II of the electron transport
chain for ATP production. Complete
oxidation of glucose by the TCA cycle
results in maximal ATP production.
In proliferating cells such as lympho-
cytes, the mitochondrion takes up
a new role as a biosynthetic hub, con-
verting metabolites such as pyruvate
and glutamine into intermediates uti-
lized by other biosynthetic pathways.
Despite the potential ability to take
up lipids from the extracellular environ-
ment, the lipids used for membrane
synthesis during lymphoid growth are
generated de novo from glucose
with TCA-cycle intermediates (Bauer
et al., 2005). Glucose-derived citrate,
generated from the condensation of
acetyl-CoA with OAA, is exported176 Immunity 27, August 2007 ª2007 Elsfrom the mitochondrion to the cytosol
and converted back to acetyl-CoA by
ATP citrate lyase (ACL). Shunting of
glucose through this ‘‘truncated TCA
cycle’’ generates a source of acetyl-
CoA for the biosynthesis of lipids in-
cluding membrane phospholipids and
cholesterol. In addition, this cytosolic
pool of citrate-derived acetyl-CoA is
essential for the production of sphin-
gomyelin, a required component of
lipid rafts, and isoprenoid moieties in-
cluding farnesyl and geranyl-geranyl
groups that modify raft-associated
signaling proteins. Akt positively regu-
lates this process by phosphorylating
ACL (Berwick et al., 2002). Inhibition
of ACL results in decreased glucose-
dependent lipid synthesis and im-
paired cell proliferation (Hatzivassiliou
et al., 2005).
The amino acids aspartate, aspara-
gine, arginine, glutamate, and proline
needed for increased translation are
also derived from TCA-cycle interme-
diates. One consequence of using
TCA-cycle intermediates for biosyn-
thesis is that the OAA needed as an ac-
ceptor for pyruvate-derived acetyl-
CoA must be regenerated so that the
integrity of the TCA cycle could be
maintained. This can be achieved
through the stepwise oxidation of glu-
tamine in proliferating cells. Glutamine
is deaminated in the mitochondria for
generation of a-ketoglutarate, which
when metabolized through the TCA
cycle serves to regenerate the OAA
consumed by biosynthesis. In addi-
tion, glutamine acts as an amine donor
in purine biosynthesis and in produc-
tion of nonessential amino acids. This
may explain why glutamine is an es-
sential metabolite for T cell prolifera-
tion (Griffiths and Keast, 1990).
Mitochondria Directly
Contribute to T Cell Activation
Initial TCR signal transduction in a qui-
escent cell leads to enhanced mito-
chondrial ATP production as a result
of Ca2+-dependent stimulation of
TCA-cycle activity. Inositol 1,4,5-tri-
sphosphate (IP3) generated after
TCR ligation promotes the release of
Ca2+ from endoplasmic reticulum (ER)
stores. Ca2+ released from the ER is
rapidly taken up by mitochondria, re-
sulting in the stimulation of Ca2+-evier Inc.dependent TCA-cycle enzymes that
in turn generate an increased rate of
oxidative phosphorylation (Krauss
et al., 2001). This burst of ATP fuels
the initial steps of receptor-mediated
signal transduction. However, when
TCR signaling is sustained, depletion
of ER Ca2+ stores can lead to a sus-
tained influx of extracellular Ca2+. Un-
der these conditions, Ca2+-dependent
stimulation of TCA-cycle dehydroge-
nases in glycolytically-converted lym-
phocytes results in an elevation of mi-
tochondrial NADH to a level greater
than that needed to sustain mitochon-
drial respiration (Jones et al., 2007).
One consequence of a persistently
saturated electron transport chain is
an increase in the production of reac-
tive oxygen species (ROS). Although
ROS is toxic in many biological set-
tings, there is evidence that its genera-
tion may play a critical role in shaping
the T cell response (Chaudhri et al.,
1986), potentially by stimulating nucle-
otide biosynthesis and S phase entry.
Thus, mitochondrial-dependent ROS
may act as an important second mes-
senger that indicates when sufficient
energetic conditions exist to support
T cell proliferation.
Intracellular Sensors of
Bioenergetics Can Suppress T
Cell Activation
Recent advances in understanding
how growth and proliferation are regu-
lated have led to the identification of
metabolic control pathways that regu-
late many aspects of anabolic and cat-
abolic metabolism. Although many of
these pathways have been studied ex-
tensively in a metabolic context (dia-
betes, vascular injury, and exercise),
their significance to T lymphocyte
biology remains unknown. One such
pathway is the energy-sensing path-
way mediated by the AMP-activated
protein kinase (AMPK). AMPK is an
ancient regulator of anabolic and cata-
bolic metabolism found in all eukary-
otes (Carling, 2004). Under conditions
of energetic stress, AMPK is activated
by the serine-threonine kinase LKB1 in
a reaction dependent on the cellular
ratio of AMP to ATP. The net result of
AMPK signaling is the engagement of
ATP-generating pathways and inhibi-
tion of ATP-consuming processes.
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bolic control of proliferating cells in-
cluding the regulation of protein
translation through stimulation of
TSC1-TSC2 complex-mediated inhibi-
tion of mTOR (Inoki et al., 2003) and
through modulation of the cellular rates
of glycolysis and b-oxidation (Buzzai
et al., 2005). AMPK was recently dem-
onstrated to be activated by TCR-
dependent Ca2+ signals (Tamas et al.,
2006), although the impact of recep-
tor-mediated AMPK activation on T
cell function remains unknown.
Recent reports have implicated the
G1-S cell-cycle checkpoint regulator
p53 in coordinating control of the cell
cycle with changes in cellular metabo-
lism. Bioenergetic stress stimulates
p53 activity via AMPK, which can in-
duce p53-dependent proliferative ar-
rest in response to ATP limitation
(Jones et al., 2005). p53 activity favors
the production of ATP by OXPHOS
through the transcriptional regulation
of the fructose-2,6-bisphosphatase
TP53-induced glycolysis and apopto-
sis regulator (TIGAR) and the synthesis
of cytochrome c oxidase (SCO2) sub-
unit of complex IV of the electron
transport chain (Bensaad et al., 2006;
Matoba et al., 2006). TIGAR negatively
regulates glycolysis by degrading
fructose-2,6-bisphosphate, an alloste-
ric activator of the glycolytic enzyme
6-phosphofructo-1-kinase (PFK-1).
SCO2 is required for assembly of the
cytochrome C oxidase (COX) com-
plex. Loss of p53-dependent regula-
tion of SCO2 cripples the mitochon-
drial respiratory chain and promotes
a switch in ATP production from
OXPHOS to glycolysis. Thus, in addi-
tion to having well-documented roles
in cell-cycle arrest and cell viability,
p53 may regulate the metabolic switch
from aerobic glycolysis to OXPHOS
and thus facilitate the return of a lym-
phocyte to an inert or anergic state.
Final Thoughts
Recent advances in understanding the
crosstalk between signal transduction
and metabolic pathways have led to
better understanding of how T lympho-
cytes regulate their bioenergetics for
meeting the challenge of proliferation.
Future work will focus on the molecular
mechanisms by which T cells regulatebiosynthetic pathways. A number of
questions remain. For example, why
is glutamine such a critical metabolite
for T cells? Proliferating lymphocytes
consume 10-fold more glutamine than
any other amino acid. As a result, im-
munologists routinely supplement their
culture medium with additional gluta-
mine. The basis for this additional re-
quirement for a nonessential amino
acid is poorly understood. Another
question is how do lymphocytes con-
vert from blastogenesis (cell growth)
to proliferation (division) after activa-
tion? One possibility is through cyto-
kine-mediated stimulation of pathways
that activate ribose-sugar production
and nucleotide biosynthesis. Alterna-
tively, mitochondrial-dependent ROS
production triggered by Ca2+ signals
may act as the molecular switch
that regulates this conversion. Finally,
does the costimulatory receptor-de-
pendent regulation of glucose uptake
contribute directly to the regulation of
T cell activation? For example, does
the resulting glucose-dependent syn-
thesis of sphingomyelin, an integral
component of lipid rafts, and isopre-
noid moieties (including farnesyl and
geranyl-geranyl groups) used for mod-
ifying raft-associated signaling pro-
teins contribute to the stable formation
of the immune synapse and signaling
lipid rafts that sustain T cell progres-
sion through the cell cycle? How these
metabolic issues impact on T cell biol-
ogy is poorly understood.
Another unanswered question is
whether metabolic factors influence T
cell fate. For example, does inade-
quate nutrient uptake or metabolism
contribute to the induction of anergy
or influence the development or sur-
vival of regulatory T cells? What is the
influence of internal metabolic regula-
tors such as AMPK and p53 on T cell
biology? Are transcription factors,
such NFAT and Foxp3, that control T
cell differentiation influenced by bioen-
ergetic factors? The answers to these
questions could result in the identifica-
tion of key metabolic pathways re-
quired for supporting T cell growth,
proliferation, and survival and lead to
new therapeutic strategies for the
treatment of cancer and immune dis-
orders such as autoimmunity and
transplant rejection.ImmunityREFERENCES
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